Print

Purpose

This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.

Condition

Eligibility

Eligible Ages
Over 12 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Histological or cytological confirmation of recurrent/metastatic nasopharyngeal cancer with either EBV or non-EBV-associated cancer. The following subgroups are included: - EBER/EBV-negative (HPV+/-) - EBER/EBV-positive (HPV+/-) - Recurrent/metastatic (stage IV-B as defined by the International Union against Cancer [UICC] and American Joint Committee on Cancer [AJCC] staging system for nasopharyngeal cancer [NPC], eighth edition) or recurrent NPC after curative treatment. For recurrent NPC, more than 6 months between the last dose of radiotherapy or chemotherapy and the date of recurrence. - Measurable disease based on RECIST v 1.1 as determined by the site. Note: Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

Exclusion Criteria

  • Disease that is suitable for local therapy administered with curative intent. - Prior systemic therapy administered in the recurrent or metastatic setting. Participants who develop disease recurrence within 6 months from curative intent chemoradiation will be excluded. - Rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator. - Active or untreated central nervous system (CNS) metastases (e.g., brain or leptomeningeal), as determined on computerized tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments. Participants who have prior therapies for brain or leptomeningeal metastasis and have been stabilized ≥ 1 month and have discontinued systemic steroid therapy (>10 mg/day prednisone or equivalent) ≥ 1 month prior to enrollment are eligible. Other protocol-defined inclusion and exclusion criteria apply.

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Toripalimab + cisplatin (or carboplatin) + gemcitabine 		Participants will receive the triple combination of cisplatin, gemcitabine and toripalimab (Chemotherapy-based treatment phase) followed by single-agent toripalimab (Maintenance treatment phase). The use of cisplatin can be substituted with carboplatin from cycle 2 onwards.
  • Drug: Toripalimab
    Participants will receive toripalimab via intravenous infusion (IV) on Day 1 every 3 weeks (Q3W) during the Chemotherapy-based treatment phase and Maintenance treatment phase.
    Other names:
    • JS001
    • TAB-001
    • CHS-007
  • Drug: Cisplatin
    Participants will receive cisplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
  • Drug: Gemcitabine
    Participants will receive gemcitabine via IV on Day 1 and Day 8 Q3W during the Chemotherapy-based treatment phase.
  • Drug: Carboplatin
    In the event of cisplatin-related nephrotoxicity or at the discretion of the investigator due to cisplatin-related poor tolerability, carboplatin can substitute for cisplatin use from cycle 2 onward. These participants will receive carboplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.

Recruiting Locations

University of Arkansas for Medical Sciences
Little Rock, Arkansas 72205
Contact:
Constance Brown
brownconstance@uams.edu

University of California, Irvine
Irvine, California 92697
Contact:
Shirin Attarian
sattari1@hs.uci.edu

University of California, San Francisco
San Francisco, California 94115
Contact:
Luchia Andemicael
Luchia.Andemicael@ucsf.edu

Emory Winship Cancer Institute
Atlanta, Georgia 30322
Contact:
Madison Stallings
madison.miller.stallings@emory.edu

Boston Medical Center
Boston, Massachusetts 02118
Contact:
Samantha Reilly
617-638-8271
samantha.reilly@bmc.org

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York 10016
Contact:
Jessica Ramcharan
Jessica.ramcharan@nyulangone.org

University of Cincinnati Medical Center
Cincinnati, Ohio 45219
Contact:
Audrey Romano
cragoay@ucmail.uc.edu

Cleveland Clinic
Cleveland, Ohio 44195
Contact:
Bridget Bush
bushb@ccf.org

Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin 53226
Contact:
Sarah Kaehny
skaehny@mcw.edu

More Details

NCT ID
NCT06457503
Status
Recruiting
Sponsor
Coherus Biosciences, Inc.

Study Contact

Clinical Operations Team Clinical Operations
800-794-5434
clinicaltrials@coherus.com

Detailed Description

The primary objective of this study is to evaluate the efficacy of toripalimab in combination with chemotherapy (cisplatin and gemcitabine), as measured by objective response rate (ORR) assessed by a Blinded Independent Central Review Committee (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in first-line recurrent metastatic nasopharyngeal cancer participants (both Epstein-Barr virus (EBV) and non-EBV-associated).

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.